Claims:Claims We Claim 1. A pharmaceutical composition of solid oral unit dosage form comprising sodium alginate polymer chemically crosslinked with bi- and/or trivalent ions for controlling the release of drug/bioactives at specific time and at specific sites. 2. A pharmaceutical composition of solid oral unit dosage form comprising sodium alginate polymer chemically crosslinked with bi- and/or trivalent ions for controlling the release of drug/bioactives at specific time and at specific sites wherein the said pharmaceutical composition is free from tableting process of granulation or coating. 3. The pharmaceutical composition of solid oral unit dosage form of claim 1 wherein the said specific site is gastrointestinal (GIT) site. 4. The pharmaceutical composition of solid oral unit dosage form of claim 1 comprising a capsule formulation selected from the group consisting of capsules, tablets in capsules, bilayer tablet, single- or multi-layered capsule. 5. The pharmaceutical composition of solid oral unit dosage form of claim 4, wherein the capsule formulation is delivered as immediate, extended-, sustained-, lag-, pulsatile-, delayed-, modified drug release (MDR), or any combinations of profiles at specific time and site. 6. The pharmaceutical composition of solid oral unit dosage form of claim 4, wherein the capsule formulation is selected from the group consisting of powder, pellets, enteric-coated granules, tablets. 7. The pharmaceutical composition of solid oral unit dosage form comprising sodium alginate polymer chemically crosslinked with bi- and/or trivalent ions for controlling the release of drug/bioactives of claim 1 wherein the said drug is selected from a group consisting of water-soluble, water-insoluble, acid-labile, non-acid labile, proteins and peptides. 8. The pharmaceutical composition of solid oral unit dosage form of claim 4 wherein the said capsule comprises a shell made of blended and/ or cross-linked natural polymer or synthetic polymer. 9. The pharmaceutical composition of solid oral unit dosage form of claim 4 wherein the said capsule formulation comprises capsule shell comprising 0.1-6% w/v aqueous solution of sodium alginate, 0.05 to 18%w/v of bi- and/or trivalent ions in the form of their salts and 0.01 to 10% w/v of polymers. 10. The pharmaceutical composition of solid oral unit dosage form of claim 9 wherein the said polymer is cross-linked with bi- and/ or trivalent ions in the form of their salts and or blended with natural or semi-synthetic or synthetic polymer or their combination. 11. The pharmaceutical composition of solid oral unit dosage form of claim 4 wherein the said capsule is tough and thick and wherein the said strength and toughness is achieved by increasing the number of capsule layers. 12. A pharmaceutical composition of solid oral unit dosage form comprising sodium alginate polymer chemically crosslinked with bi- and/or trivalent ions for controlling the release of drug/bioactives at specific time and at specific sites wherein the drug/bioactives are delivered in colon for treatment of IBD or cancer. , Description:Polymer based formulation for release of drugs and bioactives at specific GIT sites Related Application This application is being filed as a Complete Application with the Indian Patent Office, Mumbai as of April 18, 2017. FIELD OF INVENTION The present invention provides desired drug/bio-active release formulation in solid dosage form comprising variable physico-chemical properties of Active Pharmaceutical Ingredients (APIs) and other bio-actives including proteins by means of polymer capsule as a unit dosage form. The above said dosage form comprises natural polymer example, sodium alginate with bi- and/or trivalent ions chemically balanced cations to control the release of drug/bio-actives at specific time and at specific GIT sites. BACKGROUND OF THE INVENTION Solid dosage forms and such drug delivery systems with oral route, remains the most desired and accepted route of administration. Oral dosage systems are able to release the drug at a constant rate for a given time period with multiple release profile/s are thus of interest. Conventional solid dosage forms consist of active agent and biologically inert auxiliary substances which are the pharmaceutical excipients. Conventional dosage forms release the drug following which drug is very rapidly dissolved and quickly builds up to a maximum high concentration in GIT. The result is an undulating concentration of the drug in the stomach or intestine, thus in the systemic circulation and tissues. The dosage form may thus release high of or low concentrations of drugs which may under-serve the patient's needs. Often, this may cause problems in maintaining therapeutic drug levels over only brief duration of time which may either lead to an insufficient efficacy provoking an excessive drug dumping. Therefore, for the successful pharmaco-treatment, an ideal drug delivery system should be (a) able to deliver the drug at a rate to co-relate in vivo bioequivalence, and (b) deliver the drug to its targeted site, for example, as in the case of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and colonic cancer. The conventional pharmaceutical formulation strategies do not meet these delivery abilities required by specific conditions or diseases. Various controlled drug delivery systems (CDDS) have been developed with aspects of time and spatial control of drug release. CDDS are conventionally achieved by following approaches, i) diffusion controlled, ii) degradation or erosion controlled, iii) osmotic controlled and iv) swelling controlled. This results with constant uniform concentration of drug in blood and tissues over a period of time, with the following advantages: (i) reduced amount of drug administered reduces the problems of side effects, improving the safety of therapy, (ii) the patient compliance is achieved with such types of dosage forms, as the frequency of administration is considerably lower. In CDDS, the dosage form has uniform packing characteristics over a range of different particle size distributions and is capable of processing into various solid dosage forms viz. tablets, capsules, pellets, enteric coating, etc. Conclusively, rate of drug release is controlled by the rate of water penetration into the dosage form matrix. In order to achieve the desired drug release profile, various rate controlling polymers are added into the dosage form. This increases the process and thus the cost of the therapy. However, the drug dumping is associated especially with such unit dosage forms. Further, various specialized technologies such as, osmotic controlled release formulations require number of processing operations which subsequently increases the processing time. Multiple processing of unit dosage form includes coating with specific polymers, e.g. enteric coating (Time controlled drug delivery systems, In: A.T. Florence, J. Siepmann (Eds.) Modern Pharmaceutics Volume 2: Applications and Advances, Informa Healthcare USA; Inc., New York, NY; 2009; 1-22). Newer solid dosage forms are envisioned to achieve the drug and other actives to be released at various GIT sites. However, all solid dosage forms overrides the physiological implications, including the gastric pH, varied gastric retention times and other physiological limitations including the organ emptying time. For example, many drugs (e.g. Omeprazole, esomeprazole, pantoprazole, etc.) are unstable in stomach pH thereby results in drug degradation and hydrolysis, ineffective drug absorption and lowered therapeutic efficacy. This is overcome by process technology now routinely practiced as a ‘pelletization process’ followed by enteric coating using pH sensitive polymers (example, Eudragit). While, circadian rhythms are of great significance in therapeutics such in selecting the specific time of drug administration which directly influences its pharmacokinetics, adverse effects, efficacy and overall therapeutic outcome. Chronopharmaceutics provides drug release that ideally matches the circadian rhythm (24 hour) of the body in association with a specific disease, for e.g. hypertension (US6229396). The chronopharmaceutical technologies based on physical and/or chemical activation for controlled drug release that is intended for different route of administration (Adv Drug Deliv Rev., 2010, 62, 898–903). Several diseases, wherein the symptoms are most intense during night time or early morning, for example, cardiovascular diseases, bronchial asthma, duodenal ulcer, osteoarthritis, etc. are shown to follow circadian rhythms. Thus, providing treatment at the required hour would mean a more logical and clinically relevant approach to development of oral pulsatile drug delivery systems. Currently, there are major roadblocks for the successful transition of such system to reach technology to patient. These include the challenges to identify adequate (i) Suitable polymers, (ii) rhythm engineering modeling and their system biology and (iii) regulatory guidance. On the other hand, pulsatile drug delivery systems have gained increasing interest during recent years because of its ability to release the drug rapidly and completely after a defined lag time. Pulsatile release profiles are suitable for drugs with (1) higher first-pass metabolism, (2) which develop biological tolerance, (3) which are targeted to a specific site in GIT, such as colon, (4) which need protection from degradation, and to meet the chronotherapeutical diseases. Ambulatory blood pressure has reported to exhibit diurnal pattern with a surge in the early morning time which is considered to be a major factor behind high risk of cardiac death, ischemic and hemorrhagic stroke. Therefore, there is a need of an antihypertensive drug to have higher plasma concentration for morning surge in blood pressure9, 10, 11. Furthermore, various formulation strategies to target the colon include the polymeric coatings of the dosage form to provide the delayed drug release because of the degradation of coating facilitated by presence of either change in pH, pressure, time-dependent polymeric films or microorganism flora. Colon targeted drug delivery system need to overcome the hurdles in the form of acidic pH of stomach and slightly alkaline pH in small intestine. They are expected to initiate drug release in large intestine. These systems work on the principle of solubilization of polymer coating at alkaline pH above 7. Polymers such as Eudragit L100 which is soluble above pH 5.5 to 6.5 and Eudragit S100, soluble above pH 7 are commonly used. The wide variety of enzymes, such as glucoronidase, xylosidase, arabinosidase, amylase, pectinase, xylanase, galactomannanase, nitroreductase, azoreductase, deaminase, urea dehydroxylase have been reported to produce micro-biota of colon. Polysaccharides of natural origin obtained from plant, algal, animal or microbial origin such as calcium pectinate, chitosan, chondroitin sulphate, galactomanan, and amylose are mostly used for micro-biota-activated coatings. There are few issues from the viewpoint of regulatory bodies associated with azo-compounds such as firstly, the need for an organic solvent for their solubilization and secondly non-established safety profile. In general, to achieve drug delivery to colon typically comprises solid dosage forms coated with pH resistant polymers. Colon targeting is achieved by using biodegradable polymers such as cellulose acetate pthalate and shellac. On the other hand, enteric coating is achieved by using various acrylic polymers. Pressure-dependent devices are meant to be ruptured because of the relatively elevated pressure in large intestine compared to small intestine due to peristaltic movement. Finally, time-dependent coatings releases the pay load in colon as a consequence of either of the following mechanisms, which are, timed erosion, disintegration or enhanced permeability irrespective of above mentioned physiological variables. It has been hypothesized that, there is a marked decrease in the pH of proximal large intestine of IBD patients. This could be the cause in few of the instances, that coating of Eudragit S100 has failed to dissolve as intact tablet. On the other hand, as revealed by scintigraphic evaluation, tablets coated with Eudragit L100, were found to dissolve in the distal small intestine (Eur. J. Pharm. Sci.,2013, 49, 712-722; Int. J. Pharm, 2013, 457, 372-395). US6228396 discloses a colonic drug delivery composition comprising a starch capsule containing drug. Colon targeting is achieved by means of a coating comprising of a pH sensitive material, a redox sensitive material or a material which could be broken down by the enzymes or microbiota present in the colon. Capsule formulations containing API mesalamine for colon targeting is available in market (e.g. Delzicol, Apriso, Pentasa). Similarly, tablet formulations coated with a pH dependent coating which dissolves above pH 7 are also available in market (e.g. Asacol HD, Lialda). Commercially, there are various solid dosage forms with widespread therapeutics for oral administration, for example, Delzicol?, Apriso?, Pentasa?. US5482718 and US6039975 disclose colon-targeted delivery system wherein the core is comprised of a drug and a carrier and the said core is coated with an erodible polymer layer with/without Eudragit?. The use of pH-dependent polymers in combination with acidic/amphoteric drugs such as measalamine bears several difficulties. The desired drug delivery profile from modified release formulations containing ionisable drugs and/or ionic polymers such as enteric coating can be affected by pH and composition on intestinal fluids (Journal of Pharmacy and Pharmacology; 2014; 1-10). US 5171580, US6039975, WO2011045775, WO 2005030173 and US4871549 disclose coated drugs maximizing the use of excipients in the formulation leading to increase in the number of manufacturing processes. In general, in order to achieve CDDS, the technologies involve tableting process and the use of coating of solid dosage forms with different polymers. Essentially, the pharmaceutical process involves multi-steps and use of multiple excipients. And yet the ‘tunability’ to achieve the control over the drug release profiles is questionable with often drug dumping and lower patient compliance. In the present invention, Applicants propose a non-tableting, non-coating platform (capsule as a solid dosage form) using natural polymer/s to control the release of drug/bioactives at specific time and at various specific GIT sites. The rate of release of actives is achieved as immediate-, extended-, sustained, lag-, pulsatile-, or delayed-drug release profiles (e.g. site – colon delivery). Herein, capsules as a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced ions to control the release of drug/bio-actives at specific time and at specific GIT sites are demonstrated. Summary of the Invention The present invention provides solid dosage formulation in the form of capsule to achieve multiple drug dissolution profiles. The dosage form protects degradation of the drug in gastric environment (APIs e.g. Omeprazole, esomeprazole, pantoprazole and all grouped azoles), or achieve controlled /extended release of drug/bio-actives, and attain lag or pulse release profile (e.g. Metoprolol, Amlodipine, etc.). The dosage form also achieves the delayed release in small or large intestine or at colon site (e.g. Mesalamine, budesonide, infliximab, peptides, proteins or other bioactives etc.). The preparation of such solid dosage formulation is also provided. The invention also encompasses that such modified drug dissolution platform is useful to supplement the nutraceuticals or dietary minerals with divalent cations (e.g. Na+, Mg++, Ca++). The present invention relates to a drug delivery formulation in the form of polymer capsules for delivering different drugs and bioactives at various GIT sites, inclduing stomach, intestine and colon having varied drug release profiles. The capsule of the present invention achieves the delayed release of the anti-inflammatory or anticacner drugs, e.g. mesalamine, 5-flurouracil, etc. for colon delivery. The formulation composition reported in the present invention does not involve application of coating step by using any of the available enteric or biodegradable polymers nor any other excipient. The present invention comprises the dosage form using polymer of natural origin, sodium alginate which is resistant to acidic pH. The thickness and toughness of the polymer/s is so adjusted that, it remains intact during its transit through stomach and intestine. Once the capsule reaches colon, it will achieve the burst release of the drug because of the swelling of polymer at higher pH values and also by subsequent rapid erosion. The release profiles achieved are highly essential in treating Crohn’s disease, colon cancer, Irritable Bowl Syndrome (IBS) and other GI-related disorders. One aspect of the invention is to design the capsules using alginate crossed linked with multi-cations in the form of Form-Fill-Seal (FFS) process for site-specific delivery as colon targeting. BRIEF DESCRIPTION OF FIGURES Figure 1. Schematic for preparation of capsule dosage form comprising polymer and ions and the Dimensions of drug releasing polymer capsule using multi ions of alginate gel. Figure 2. Varied release profiles of APIs with alginate and/or bi- or trivalent ions and/ or polymers. Figure 3. Dissolution profile of H+ proton pump inhibitor Omeprazole- a pH unstable API. Figure 4. Dissolution profile of Metformin Hydrochloride showing Immediate Release (IR) Profile. Figure 5. Dissolution profile of Metoprolol tartrate in 0.1M HCl (4 Hrs), pH 6.8 Phosphate buffer (4 Hrs) and pH 7.6 Phosphate buffer (4 Hrs). Figure 6. Dissolution profile of Mesalamine in 0.1M HCl (2 Hrs), pH 6.0 Phosphate buffer (1 Hr) and pH 7.2 Phosphate buffer (3 Hrs). DETAILED DESCRIPTION The present invention is related to a polymer based formulation for release of drugs and bio-actives at GIT specific sites. In one embodiment, the invention describes a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced cations to control the release of drug/ bio-actives at specific time and at specific GIT sites. Herein, the applicant details a modified drug releasing pharmaceutical formulation as a capsule dosage form comprising Form-Fill-Seal (FFS) capsule processing. This brings ease of administration, subsequently avoiding inconvenient route of administration for dosage forms like suppositories and enemas. Avoidance of systemic absorption of drugs and consequently its unwanted distribution to tissues in the body is also achieved. This is applicable for site specific drug targeting for efficient local treatment of large bowel diseases, such as inflammatory bowel disease, ulcerative colitis, amebiasis, and colonic cancer. The polymeric capsule can deliver drugs or proteins and peptide drugs. Rectal administration is also limited by availability of lesser number of dosage forms (solutions, foams, enemas, and suppositories) and drug also remains localized to rectum and distal colon if administered by this route. In another embodiment, the invention describes the preparation of said formulation and its release profile for wide-ranging therapeutics as a “capsule” prepared by finely-tuned composition of bi- and/or trivalent cations and natural and/ or synthetic polymer/s or combination thereof to control the release of drug/bioactives at specific time and at specific GIT sites. The term “modified release” includes, but is not limited to, immediate-, extended-, sustained-, lag- and pulsatile-, or delayed-, or combination of drug release profiles in pharmaceutical formulation. The present invention demonstrates a novel composition that offers greater multiplicity and flexibility in the release profile to be obtained with finely tuned natural polymer, sodium alginate using di- and/or tri-valent cations and natural/ semi-synthetic/ synthetic polymer. The relative ionic affinity and ability to form gels has been extensively studied for natural polymer, sodium alginate and a range of divalent cations is established the following series for the concentration of divalent cations required to bring about gelation of alginate: Ba